Free Trial
NASDAQ:PRTG

Portage Biotech Q3 2024 Earnings Report

Portage Biotech logo
$5.82 +0.09 (+1.48%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Portage Biotech EPS Results

Actual EPS
-$3.60
Consensus EPS
-$5.40
Beat/Miss
Beat by +$1.80
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, February 28, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Portage Biotech's Q3 2025 earnings is scheduled for Tuesday, August 26, 2025

Earnings Documents

Portage Biotech Earnings Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
PRTG Portage Biotech Inc. - Seeking Alpha
Portage Biotech Regains Nasdaq Compliance
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:PRTG), a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

View Portage Biotech Profile

More Earnings Resources from MarketBeat